The best treatment will depend on local resistance patterns, but standard triple therapy is an increasingly unlikely candidate
Since the isolation and identification of Helicobacter pylori by the consequently Nobel prize winning pathologist Barry Marshall and gastroenterologist Robin Warren in 1982, 1 it quickly became evident that half of the world's population is infected with this organism. 2 The scientific and medical community soon realised that H pylori infection does not always cause clinical disease but strongly affects the relative risk of various disorders in the upper gastrointestinal tract (gastritis, peptic ulcer disease, gastric cancer, mucosa associated lymphoid tissue lymphoma) and sometimes beyond (idiopathic thrombocytopenic purpura, idiopathic iron deficient anaemia).
The number of guidelines for the management of H pylori infection from various societies (including the American College of Gastroenterology, Maastricht IV Consensus Report, Japanese Society for Helicobacter Research, Second Asia-Pacific Consensus Guidelines, National Institute for Health and Care Excellence) attests to the difficulty in achieving successful eradication of this highly adaptive pathogen. For effective treatment, complex multidrug regimens are required. High bacterial load, high gastric acidity, type of Helicobacter strain, low compliance, and smoking are associated with treatment failure, but growing antibiotic resistance-in particular against clarithromycin-seems to be the major cause of poor outcome. The efficacy of standard triple treatment, which includes a proton pump inhibitor, clarithromycin, and amoxycillin or metronidazole administered for seven days, is falling to unacceptable levels in most countries as the antibiotic resistance to clarithromycin and metronidazole increases. In regions with a low prevalence of resistance to clarithromycin (<15%) such as the United Kingdom, 5 standard triple treatment is still recommended as empirical first line treatment.
In a linked paper (doi:10.1136/bmj.h4052) Li and colleagues go beyond conventional meta-analysis to report a comprehensive network meta-analysis filtering even more information out of the thick jungle of published trials evaluating treatments for the eradication of H pylori.
6 After a thorough selection process, they combined the data of 143 first line eradication studies evaluating 14 different treatment regimens that varied in dosages and type of proton pump inhibitors, antibiotics, and duration of treatment. The authors analysed data from a total of 32 056 patients.
Rather than simply comparing trials that evaluated the same treatments, a network meta-analysis extends the number and type of studies being analysed for clinical decision making. This methodology also allows researchers to make indirect comparisons across trials and among treatments that have not been tested head to head, as long as the trials are linked by a common treatment arm.
Standard triple treatment for seven days emerged at the bottom of the ranking by both direct and indirect comparisons. Previously recommended worldwide, this treatment regimen is now the least effective in the intention to treat analysis, with an eradication rate of only 73%. Top of the ranking was seven days of concomitant treatment, combining proton pump inhibitors with three other antibiotics (often amoxicillin, clarithromycin, and 5-nitroimidazole), but this result is predominantly based on one study of 119 patients compared directly with the standard triple treatment. A levofloxacin based triple treatment performed disappointingly in a seven day regimen, with only 76% overall success, which improved to 90% when given for 10 or 14 days.
Not surprisingly, prolonging the treatment over 10 or 14 days improved the efficacy of most regimens, but at the cost of a trend towards higher rates of adverse events. The consideration of tolerance and adverse events associated with different regimens is one of this study's strengths. The benefits of adjuvant treatments such as probiotic supplementation is of special clinical interest as this could be a simple way to enhance the efficacy of a regimen and potentially reduce treatment related side effects, which otherwise can result in poor compliance. The seven days of standard triple treatment supplemented with probiotics performed best in terms of tolerance.
Since live non-pathogenic microbial food products seem to improve tolerability and the outcome of antibiotic treatment, 7 there is no harm in encouraging patients to eat probiotic yoghurts while further evidence is awaited on exact dosing and duration, and whether multistrain milk based fermented preparations such as yoghurt or kefir are sufficient, or pure single strain supplementation in capsule form is required. When counselling patients about a detailed treatment plan and how important it is 
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to take all prescribed drugs correctly, it might also be helpful to recommend regular consumption of probiotic yoghurts for a few weeks. The risk-benefit ratio and safety profile are favourable for probiotics.
Network meta-analysis is most valid when combining similar studies conducted in similar populations. This is unlikely to be the case for treatment studies from different regions of the world, as H pylori strains from different geographical regions vary widely in their virulence, and the likelihood of resistance to antibiotics. In the subgroup network meta-analysis specified by country of origin, Li and colleagues were unable to identify the superiority of any individual treatment regimen. Unfortunately, only a few trials recorded data on antibiotic resistance, so we cannot judge the comparability of included studies, and confident interpretation of the overall findings is difficult.
Although network meta-analysis is helpful in comparing different treatment strategies, it cannot overcome the need to obtain local antibiotic resistance patterns or susceptibility testing before selecting the best available treatment in any particular region.
Sometime in the distant future, vaccination against H pylori might solve the problem by preventing infection from early childhood onwards. 8 Until then we will have to keep looking for the most effective antibiotic eradication regimen with the best safety profile, but it seems unlikely that this will be a "one size fits all" treatment suitable for patients all over the world.
